TP53 and breast carcinoma: Given that only 28% of the breast cancers analysed in this work harboured truncating mutations in TP53, we assumed that other mechanisms not associated with TP53 mutation status, including p53 isoform expression, may affect breast cancer outcomes via the p53 pathway.